1. Search Result
Search Result
Results for "

PBRM1

" in MedChemExpress (MCE) Product Catalog:

14

Inhibitors & Agonists

1

Antibodies

1

Oligonucleotides

Cat. No. Product Name Target Research Areas Chemical Structure
  • HY-151532

    Epigenetic Reader Domain Cancer
    PBRM1-BD2-IN-5 is a potent PBRM1 Bromodomain inhibitor with Kd values of 1.5 μM and 3.9 μM for PBRM1-BD2 and PBRM1-BD5, respectively, and an IC50 value of 0.26 μM for PBRM1-BD2. PBRM1-BD2-IN-5 reduces the binding of full-length PBRM1 within the PBAF complex in cell lysates to acetylated histone peptide. PBRM1-BD2-IN-5 can be used to research anticancer [1].
    PBRM1-BD2-IN-5
  • HY-151538

    Epigenetic Reader Domain Cancer
    PBRM1-BD2-IN-8 (compound 34) is a potent PBRM1 Bromodomain inhibitor (PBRM1-BD2 Kd=4.4 μM, PBRM1-BD2 IC50=0.16 μM; PBRM1-BD5 Kd=25 μM). PBRM1-BD2-IN-8 shows anti-cancer activity [1].
    PBRM1-BD2-IN-8
  • HY-151529

    Epigenetic Reader Domain Cancer
    PBRM1-BD2-IN-2 is a selective and cell-active polybromo-1 (PBRM1) bromodomain inhibitor. PBRM1-BD2-IN-2 has binding affinity and inhibitory activity for PBRM1-BD2 with Kd and IC50 values of 9.3 μM and 1.0 μM, respectively. PBRM1-BD2-IN-2 can be used for the research of cancer [1].
    PBRM1-BD2-IN-2
  • HY-RS10105

    Small Interfering RNA (siRNA) Others

    PBRM1 Human Pre-designed siRNA Set A contains three designed siRNAs for PBRM1 gene (Human), as well as a negative control, a positive control, and a FAM-labeled negative control.

    PBRM1 Human Pre-designed siRNA Set A
    PBRM1 Human Pre-designed siRNA Set A
  • HY-151531

    Epigenetic Reader Domain Cancer
    PBRM1-BD2-IN-4 (compound 15) is a potent PBRM1 Bromodomain inhibitor with Kd values of 5.5 μM and 11.1 μM for PBRM1-BD2 and PBRM1-BD5, respectively, and an IC50 value of 0.2 μM for PBRM1-BD2. PBRM1-BD2-IN-4 can be used to research anticancer [1].
    PBRM1-BD2-IN-4
  • HY-151530

    Epigenetic Reader Domain Cancer
    PBRM1-BD2-IN-3 (compound 12) is a potent PBRM1-BD2 inhibitor with an IC50 value of 1.1 μM. PBRM1-BD2 Inhibitor can be used to research anticancer [1].
    PBRM1-BD2-IN-3
  • HY-151533

    Epigenetic Reader Domain Cancer
    PBRM1-BD2-IN-6 is a potent PBRM1 bromodomain inhibitor with an IC50 value of 0.22 μM. PBRM1-BD2-IN-6 shows antiproliferation activity. PBRM1-BD2-IN-6 has the potential for the research of PBRM1-dependent cancer [1].
    PBRM1-BD2-IN-6
  • HY-151534

    Epigenetic Reader Domain Cancer
    PBRM1-BD2-IN-7 is a selective and cell-active polybromo-1 (PBRM1) bromodomain inhibitor. PBRM1-BD2-IN-7 has inhibitory activity for PBRM1-BD2 with an IC50 value of 0.29 μM. PBRM1-BD2-IN-7 can be used for the research of cancer [1].
    PBRM1-BD2-IN-7
  • HY-151528

    Epigenetic Reader Domain Cancer
    PBRM1-BD2-IN-1 is a selective and cell-active polybromo-1 (PBRM1) bromodomain inhibitor. PBRM1-BD2-IN-1 has binding affinity and inhibitory activity for PBRM1-BD2 with Kd and IC50 values of 0.7 μM and 0.2 μM, respectively. PBRM1-BD2-IN-1 can be used for the research of cancer [1].
    PBRM1-BD2-IN-1
  • HY-161881

    Epigenetic Reader Domain Cancer
    SMARCA2-IN-9 (compound 11) is a SMARCA2, PBRM1 bromodomains 2 (PBRM1(2)), and PBRM1 bromodomains 5 (PBRM1(5)) inhibitor with Kd values of 1.6 μM, 2.5 μM, and 3.95 μM, respectively [1].
    SMARCA2-IN-9
  • HY-150289

    Others Cancer
    GNE-235 is a compound selective for the second bromodomain of PBRM1, with a KD of 0.28 ± 0.02 μM. GNE-235 can be used for evaluation of the cellular function of PBRM1 [1].
    GNE-235
  • HY-149026

    Epigenetic Reader Domain Others
    GNE-064 (compound 5) is a selective, orally active and highly soluble inhibitor of SMARCA4, SMARCA2 and PBRM1 bromodomains 5. GNE-064 inhibits SMARCA4 with an IC50 of 0.035 μM and inhibits SMARCA2 with an EC50 of 0.10 μM. GNE-064 possess Kds with 0.01, 0.016, 0.018 and 0.049 μM for SMARCA4, SMARCA2, PBRM1 bromodomains 5 and PBRM1 bromodomains 2, repectively. GNE-064 can be used as a chemical probe for the research of agent synthesis [1].
    GNE-064
  • HY-163410

    PROTACs Epigenetic Reader Domain Cancer
    AU-24118 is orally bioavailable proteolysis targeting chimera (PROTAC) degrader of mSWI/SNF ATPases (SMARCA2 and SMARCA4) and PBRM1 [1].
    AU-24118
  • HY-128359
    ACBI1
    5 Publications Verification

    PROTACs Epigenetic Reader Domain Apoptosis Cancer
    ACBI1 is a potent and cooperative SMARCA2, SMARCA4 and PBRM1 degrader with DC50s of 6, 11 and 32 nM, respectively. ACBI1 is a PROTAC degrader. ACBI1 shows anti-proliferative activity. ACBI1 induces apoptosis [1].
    ACBI1

Inquiry Online

Your information is safe with us. * Required Fields.

Salutation

 

Country or Region *

Applicant Name *

 

Organization Name *

Department *

     

Email Address *

 

Product Name *

Cat. No.

 

Requested quantity *

Phone Number *

     

Remarks

Inquiry Online

Inquiry Information

Product Name:
Cat. No.:
Quantity:
MCE Japan Authorized Agent: